Eczema Therapeutics Sector Forecast to Reach $49.8 Billion by 2035, Fueled by Breakthrough Biologics
At the forefront of this shift is the increasing incidence of eczema—particularly atopic dermatitis—affecting millions globally. Characterized by chronic inflammation, severe itching, and skin barrier dysfunction, eczema is most common in infants and children but can persist into or begin in adulthood. In the United States alone, over 31 million individuals are living with eczema, as reported by the National Eczema Association.
Growth Catalysts
The rising prevalence of eczema is a primary factor behind the sector's momentum. Pediatric cases continue to climb, while adult diagnoses are also increasing as awareness and diagnostic capabilities improve. Urbanization and lifestyle factors are further contributing to the surge in cases across both developed and developing economies.
Recent years have seen a paradigm shift in treatment approaches, thanks to the approval and adoption of innovative biologics such as Dupixent (dupilumab) by Sanofi and Regeneron and Abrocitinib , a selective JAK1 inhibitor by Pfizer. These advanced therapies have proven especially effective for patients with moderate to severe eczema who do not respond well to conventional treatments like corticosteroids or calcineurin inhibitors.
Barriers to Access
Despite the progress, the eczema therapeutics landscape faces notable challenges. Chief among them is the high cost of biologic therapies, which can limit access, particularly in low- and middle-income regions. Additionally, traditional treatments, though widely used, often carry risks such as skin thinning and hormonal imbalances, which can deter long-term adherence and physician recommendations.
Opportunities in Innovation and Emerging Regions
The future of eczema care lies in personalized and targeted treatments. Innovations in genomics, microbiome research, and drug delivery are paving the way for more precise therapies with fewer side effects. Emerging economies present significant untapped potential, with expanding healthcare infrastructure, government support, and rising consumer awareness around dermatological conditions.
Sector Segmentation
The eczema therapeutics industry is segmented based on multiple parameters: By Drug Class: Including corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and biologics.
Including corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and biologics. By Treatment Type: Prescription medications, over-the-counter (OTC) products, alternative therapies, and home-based remedies.
Prescription medications, over-the-counter (OTC) products, alternative therapies, and home-based remedies. By Eczema Type: Atopic, contact, seborrheic, dyshidrotic, and nummular eczema.
Atopic, contact, seborrheic, dyshidrotic, and nummular eczema. By Route of Administration: Topical applications dominate, followed by oral and injectable options.
Topical applications dominate, followed by oral and injectable options. By Distribution Channel: Hospital pharmacies, retail outlets, and increasingly, online platforms.
Hospital pharmacies, retail outlets, and increasingly, online platforms. By Patient Demographic: Infants, children, and adults form the primary treatment groups.
Regional Outlook
North America remains the global leader, benefiting from advanced healthcare systems, strong R&D activity, and favorable insurance reimbursement models. Europe also demonstrates strong momentum, especially in nations such as Germany, France, and the UK. The Asia-Pacific region is emerging as the fastest-growing geography, driven by urbanization, increased healthcare spending, and rising patient volumes in countries like India and China.
Latin America, the Middle East, and Africa, while currently smaller in scale, are poised for steady progress as investments in healthcare infrastructure and dermatological services increase.
Competitive Landscape
The eczema therapeutics field is highly dynamic, with a blend of pharmaceutical giants and emerging biotech innovators. Key players include: Sanofi S.A.
Regeneron Pharmaceuticals
Pfizer Inc.
AbbVie Inc.
Novartis AG
LEO Pharma A/S
GlaxoSmithKline plc
AstraZeneca plc
Galderma SA
Incyte Corporation
These companies are actively developing new therapies aimed at improving efficacy, reducing side effects, and expanding access across age groups and severity levels.
Recent Developments Pfizer's oral JAK1 inhibitor Abrocitinib gained FDA approval in 2023, enhancing treatment options for patients requiring systemic therapy.
gained FDA approval in 2023, enhancing treatment options for patients requiring systemic therapy. Sanofi and Regeneron are expanding Dupixent's indications through clinical trials targeting adolescents and younger children.
indications through clinical trials targeting adolescents and younger children. A wave of startups is pursuing microbiome-focused and gene-based therapies that promise long-term, sustainable relief with minimal adverse reactions.
Looking Ahead
With innovation at the forefront, the eczema therapeutics sector is set for accelerated growth through 2035. Biologic advancements, expanding global awareness, and precision medicine are redefining treatment standards, offering renewed hope to millions living with this chronic skin disorder.
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
2 days ago
- Politico
Former NIH head: We need Boston and the Bay
INFLUENCERS Times have changed since Dr. Elias Zerhouni ran the National Institutes of Health under President George W. Bush. Back then, the Republican president was keen to double the agency's budget, not cut it by 40 percent, as President Donald Trump's fiscal 2026 budget proposal calls for. 'I've been in this business for 50 years and I know a thing or two about what our fundamental drivers of success are,' said Zerhouni, who after leaving NIH served as president of global research and development at the pharmaceutical company Sanofi. 'It's not a subsidy that we're giving. It's an investment we're making. In some ways, they are really pennywise and pound-foolish,' he added. Zerhouni recalls when Republicans would never have considered such drastic steps, which he spells out in his new memoir: 'Disease Knows No Politics.' In an interview with Erin, Zerhouni talked about what drives successful research and explained why current NIH Director Jay Bhattacharya's suggestion to redistribute research dollars away from coastal powerhouse institutions is misguided. This interview has been edited for length and clarity. What do you think about Bhattacharya's push to redistribute research money to the heartland? Send the money to Pocatello, Idaho, and hope for the best. He's ignoring the mechanics of why we get these superconcentrations in Boston or in the Bay Area for technology. The notion that you pick and choose and force-feed your research enterprises is naive. You cannot do science without having access to MIT, access to Harvard, access to Boston University, access to Mass General Hospital. In Boston, you have 250,000 scientists and engineers. You need a concentration in disciplines to do science today. But couldn't government funding help build more of them? The way you do good biomedical research today is by breaking the barriers between biological science and physical sciences and computational sciences. You don't find that everywhere. That combination of talent only exists in a few places. Bhattacharya seems to say that the maldistribution of dollars is what he thinks is the disease. It's not. It's a fundamental characteristic of powerful research environments where you have multidisciplinary interactions that are constantly interacting. Places like San Francisco and Seattle and the Bay have benefited from decades of investment by universities, philanthropies, government. You can't reproduce that by just taking the money from them and sending it somewhere else and thinking you're going to get the same results. What do you make of how the NIH is functioning under Trump? I've never seen so many political appointees coordinating above the head of agencies. That is unusual. In my time, there were only two political appointees, the National Cancer Institute director and myself. It's good if you're attacking unmet needs that are really well-defined. This issue of nutritional sciences for the American people is a big one. That's a good thing if there is political will to face special interests that will come out against it, especially the agricultural lobbies that benefit from subsidies and the companies that do not want any more regulation. Same for chronic diseases. It's a problem no one has been able to address. But I don't think you're going to address that by just changing the color chemistry in Fruit Loops. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Pharmaceutical companies are charting out their artificial intelligence priorities for the next two years, according to a new report from Define Ventures. It says that most drug industry execs want to use AI to find efficiencies, reduce the cost of drug discovery and boost revenues — and they're looking for the right tech partners to help them. Share any thoughts, news, tips and feedback with Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: CarmenP.82, RuthReader.02 or ErinSchumaker.01. BUSINESS PLAN As state and federal lawmakers consider online safeguards for kids, more companies are using technology to determine their customers' ages and, if needed, block them from using riskier features. Roblox, a wildly popular gaming site, announced this week that it would start estimating users' ages before allowing teens to communicate with certain users without chat filters. The changes represent a significant step above the industry standard and a broadening of its safety work, reports POLITICO's California tech team. 'This makes Roblox the only major platform that will require age verification like facial age estimation in order to use private voice or unfiltered chat,' Ryan Ebanks, a principal product manager at Roblox, said on a call with press. 'We hope others will join us.' How it works: Roblox users 13 and older will be able to message and voice chat more freely with people they approve as 'trusted.' If users take a video selfie Roblox will analyze it against a dataset to estimate their age range. Backup options like ID verification, parental consent and participation in a Zoom call are also available. Teens can add other users, including adults, to the 'trusted' category by importing contacts or scanning their accounts' QR codes. Users identified as under 13 by the estimation technology will have their age corrected and lose access to the feature. Ebanks said all conversations on Roblox, including those that use the feature, will 'remain proactively monitored for critical harms.' Sharing images and videos over chat is also prohibited, regardless of age, and parents can choose to receive a list of who their kids add as virtual friends. Why it matters: Federal legislators are considering a bevy of options to require social media and gaming platforms to protect kids. Specifically, lawmakers are concerned with the impact of bullying, online drug sales and how certain features of social media might harm kids' mental and physical health. Last year, the Senate overwhelmingly passed a bill that would have required social media companies to design their platforms with consideration for kids' safety, but it never reached the floor for a vote in the House. Now, lawmakers are considering a variety of new bills. One idea gaining popularity is to require app stores to verify their users' ages and obtain parental consent for those under 18. Roblox's chief safety officer, Matt Kaufman, said the company is 'constantly taking input' from policymakers, but the updates aren't a response to any specific proposals.
Yahoo
2 days ago
- Yahoo
5 Common Eczema Triggers — & How to Manage Them
Eczema is one of the most common dermatological conditions out there, affecting roughly 10 percent of all Americans, according to the National Eczema Association. This chronic inflammatory condition 'causes the skin to become dry, itchy, red, and inflamed,' Dr. Debra Jaliman, MD, a dermatologist, tells SheKnows. It's a concern she frequently sees in patients in her New York City practice. In mild cases, eczema rashes can be uncomfortable or make you slightly self-conscious. But when a flare-up is in full force? That telltale itchiness can become downright unbearable. It can keep you up at night, cause emotional distress, and even lead to painful, weeping sores or skin infections. More from SheKnows How Hot Weather Can Make Eczema Worse - & What To Do About It Despite its relatively high prevalence, eczema is a complex condition that can be triggered by a range of things, from irritants in your environment, to your mental and emotional state, and to fluctuations in your hormone levels. That's why it's so important to seek treatment from a professional. 'Tailored guidance that may include over-the-counter products or prescriptions from a dermatology provider is critical in helping to manage symptoms,' Renata Block, MMS, PA-C, a physician assistant specializing in dermatology, tells SheKnows. Luckily, there are plenty of products out there to treat acute flare-ups. You can also take proactive steps to prevent outbreaks. Below, find an overview of everything you need to know about eczema, including what it is, common triggers, and how to prevent and treat flare-ups. What is eczema? Eczema is a form of dermatitis, or inflammation of the skin, that causes visible, itchy rashes. 'It can be seen on any part of the body and can show up as red, scaly spots that sometimes ooze and blister,' Dr. Alexandra Flamm, MD, a dermatologist with NYU Langone, tells SheKnows. On brown or Black skin, it can present as small, raised, itchy bumps. There are different forms of eczema too, atopic dermatitis being the most common. Across the board, eczema isn't contagious, and it's usually not painful. It often comes and goes throughout a person's life. Eczema can be connected to your environment, genetic factors, and anything that causes increased inflammation in your body; however, it's not considered an autoimmune disorder. Though it often shows up first in childhood, eczema can affect anyone at any age. It can even appear later in life in adults who never had symptoms previously. In fact, 'adult women are more likely to have persistent or adult-onset eczema,' Jaliman says. Since women disproportionately shoulder the burden of household cleaning, they're also more likely to suffer from hand eczema. If your doctor suspects that you have eczema, they may perform allergy tests or bloodwork to rule out other skin conditions that mimic it. Once you've been diagnosed, they'll equip you with tools to manage symptoms. That may include prescription-strength creams or ointments, oral antihistamines, or gentle lotions that you can purchase OTC. Common eczema triggers and how they can affect you When it comes to eczema management, 'it's important to understand what your triggers are and try to avoid them,' Flamm says. Otherwise, it could lead to a flare-up. That's when symptoms worsen noticeably — a rash may appear or spread, and you'll typically notice increased itchiness and discomfort. You might even start oozing or bleeding, which can be a sign of a severe flare-up or infection, Jaliman says. Triggers vary widely. Some are preventable; others involve natural fluctuations in your body and can't always be prevented, only addressed. Fragrance Fragrance is a very common trigger. If you have eczema, you can prevent flare-ups by using fragrance-free makeup, skincare products, body products, laundry detergents, and other household cleaning products. (Read the labels closely — you'd be surprised at how many products contain fragrances!) Flamm also recommends looking for moisturizers that are 'geared towards people with eczema-prone skin or contain ceramides, which are important building blocks for skin health.' Fluctuations in temperature or humidity Extreme hot or cold weather or the changing of the seasons can trigger flare-ups. So can prolonged exposure to water, like swimming all day or taking long, hot showers. Many patients also report that their symptoms get worse in the winter, when temps are cooler and the air is drier. Jaliman's advice? Take shorter showers, and avoid using scalding-hot water. Be sure to keep your skin adequately moisturized, and use gentle products that won't aggravate it. Irritating fabrics Many eczema patients find wool, mohair, and certain synthetic fabrics irritating to the touch, which can lead to flare-ups. Generally, Jaliman recommends that her patients wear gentle, breathable fabrics made of natural materials, such as cotton. (A pro tip from yours truly, who's dealt with eczema for years: Layer a cotton t-shirt underneath your wool sweater to create a barrier.) Allergic reactions Per Cleveland Clinic, the connection between allergies and eczema isn't entirely clear, but anecdotal reports indicate that allergic reactions can lead to flare-ups. Basically, 'anything that promotes an inflammatory environment can trigger it,' Block says. If you're allergic to any common allergens — like certain foods, pet dander, or dust mites — you'll want to steer clear of them. This will both prevent allergic reactions, which can be life-threatening, and help keep your eczema at bay. Fluctuations in your hormone levels or stress 'Hormonal fluctuations affect eczema,' Jaliman says, which is key for women and people with uteruses. At certain points in your menstrual cycle, you may notice that you're more prone to flare-ups. The same logic applies to people who are pregnant and going through perimenopause or menopause. Like most inflammatory conditions, eczema is also connected to your mental health. Surges in stress, anxiety, or depression can trigger inflammation in the body too, triggering flare-ups. If any of that applies to you, it's extra important to stay on top of your eczema management protocol. Avoid known triggers, do what you can to manage stress, and keep your skin moisturized with gentle, eczema-friendly products. How to manage eczema flare-ups Think you're experiencing an eczema flare-up? First things first, reach out to a dermatology provider. They'll be able to confirm that eczema is the culprit, identify potential triggers, and go over your treatment options. These vary depending on the location and severity of the outbreak. If the rash is mild or near your eyes, your doctor may prescribe you a non-steroid cream or recommend a non-prescription anti-itch lotion. They may also suggest that you take an oral antihistamine to reduce your body's immune response. However, if it's more severe or in a less-sensitive area, you might go home with an Rx for a topical corticosteroid. These powerful ointments work quickly to reduce inflammation and alleviate itchiness, allowing the rash to heal. (As a note, corticosteroids are not safe for long-term use and should only be used 'no more than twice a day to flared areas,' Flamm says.) You'll also want to monitor the area for infection, Jaliman adds. 'Signs include yellow crusting, weeping, swelling, or pain.' If your doctor suspects that your rash has become infected, they'll likely send you home with a topical or oral antibiotic to nip it in the bud. As a rule of thumb, avoid scratching at any rashes. 'The more you scratch, the worse it gets,' Block explains, 'as the scratching triggers an inflammatory response, which worsens the condition.' Instead, focus on reducing inflammation and keeping your skin lightly moisturized. Before you go, shop our favorite skincare brands for teens: Best of SheKnows Amanda Seyfried, Megan Fox, & More Celebrities Who Have OCD 18 Baking Soda-Free Natural Deodorants That Won't Irritate Your Sensitive Pits 24 Celebrities Living With Autoimmune Disorders
Yahoo
3 days ago
- Yahoo
Press Release: Sanofi completes acquisition of Blueprint Medicines
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases. In addition, the acquisition of Blueprint brings Sanofi an established presence among allergists, dermatologists, and immunologists which is expected to enhance Sanofi's ability to advance its growing immunology pipeline. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and EU. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM), which is characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs. The acquisition also includes elenestinib, a next-generation medicine for SM that is a potent and highly selective KIT D816V inhibitor with limited central nervous system penetration. The oral investigational ISM medication is the subject of HARBOR, a phase 2/3 study (clinical study identifier: NCT04910685). The ongoing, randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of elenestinib plus symptom-directed therapy in patients with ISM and smoldering SM. Sanofi also acquired BLU-808, an investigational oral, highly potent and selective wild-type KIT inhibitor. Wild-type KIT plays a central role in mast cell activation, which is implicated in a broad range of inflammatory diseases. The tender offer for all outstanding shares of Blueprint common stock, par value $0.001 per share expired at 17:00 EDST, on Thursday, July 17, 2025. The minimum tender condition and all of the other conditions to the offer have been satisfied, and on July 17, 2025, Sanofi accepted for payment and will promptly pay for all shares validly tendered and not validly withdrawn. Following its acceptance of the tendered shares, Sanofi completed its acquisition of Blueprint through the merger of a wholly owned subsidiary of Sanofi with and into Blueprint, pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Blueprint continuing as the surviving corporation, and becoming an indirect, wholly owned subsidiary of Sanofi. Sanofi is financing the transaction with a combination of cash on hand and proceeds from commercial paper issuances and the acquisition will not have a significant impact on Sanofi's financial guidance for 2025. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026. In connection with the merger, all Blueprint shares not validly tendered in the tender offer have been converted into the right to receive $129.00 per share in cash, without interest and subject to any withholding of taxes required by applicable legal requirements, plus one non-transferable contractual contingent right per share, representing the right to receive contingent payments of up to an aggregate amount of $6.00 per share in cash, without interest, upon the achievement of specified milestones on or prior to the expiration of the applicable milestone period. As of July 18, 2025, Blueprint common stock will cease to be traded on the NASDAQ Global Select Stock Market. About AyvakitAyvakit (avapritinib) is the first and only medicine approved by the US Food and Drug Administration (FDA) to treat the root cause of SM. It was FDA approved for the treatment of advanced SM in June 2021 and indolent SM in May 2023. It now is indicated in adults with ISM, adults with advanced SM, including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL), and adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. The medicine is approved in the EU as Ayvakyt for the treatment of adults with ISM with moderate to severe symptoms inadequately controlled on symptomatic treatment, adults with ASM, SM-AHN or MCL, after at least one systemic therapy, and adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation. Globally, the medicine is approved for one or more indications in 16 countries, including China where it is marketed by CStone Pharmaceuticals, paying tiered percentage royalties on sales. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Le Bourhis | +33 6 75 06 43 81 | Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Léa Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | Kaisserian | +33 6 47 04 12 11 | Felix Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Tarik Elgoutni | +1 617 710 3587 | Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsForward-looking statements are statements that are not historical facts. These statements may include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product, and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'will be', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful and other risks associated with executing business combination transactions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the acquisition will not be realized, risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed acquisition, disruption from the proposed acquisition making it more difficult to conduct business as usual or to maintain relationships with customers, employees, manufacturers, suppliers or patient groups, and the possibility that, if the combined company does not achieve the perceived benefits of the proposed acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Sanofi's shares could decline, as well as other risks related to Sanofi's business, including the ability to grow sales and revenues from existing products and to develop, commercialize or market new products, competition, including potential generic competition, the uncertainties inherent in research and development, including future clinical data and analysis, regulatory obligations and oversight by regulatory authorities, such as the FDA or the EMA, including decisions of such authorities regarding whether and when to approve any drug, device or biological application that may be filed for any product candidates as well as decisions regarding labelling and other matters that could affect the availability or commercial potential of any product candidates, the absence of a guarantee that any product candidates, if approved, will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the US Securities and Exchange Commission (the 'SEC') and the Autorité des marchés financiers made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. Attachment Press ReleaseSign in to access your portfolio
